Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis

  • Sakamori Ryotaro
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Yamada Ryoko
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Shinkai Kazuma
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Doi Akira
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Tahata Yuki
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Shigekawa Minoru
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Kodama Takahiro
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Hikita Hayato
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Yamada Tomomi
    Department of Medical Innovation, Osaka University Hospital, Japan
  • Tatsumi Tomohide
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan
  • Takehara Tetsuo
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan

この論文をさがす

抄録

<p>Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologic response (SVR) in patients with decompensated liver cirrhosis have not been reported. We present the first report of skeletal muscle mass improvement with the achievement of SVR for HCV in a 76-year-old woman with decompensated liver cirrhosis. After achieving SVR through ledipasvir/sofosbuvir treatment, the patient showed an improvement in her liver function and an increase in her skeletal muscle mass. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 60 (5), 745-750, 2021-03-01

    一般社団法人 日本内科学会

被引用文献 (1)*注記

もっと見る

参考文献 (13)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ